SOFINNOVA-PARTNERS
30.6.2021 10:02:11 CEST | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases. The startups, AAVantgarde Bio , Alia Therapeutics , and Borea Therapeutics , are developing promising new therapies for rare, genetic diseases.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, commented: “These investments mark an important step in our mission to support the excellent scientific research coming out of Italian academic and research centers. They also highlight the exceptional flow of new investment opportunities in Italian biotech, and the important role that venture capital plays in enabling ground-breaking treatments to reach patients suffering from rare, genetic diseases who today have very few therapeutic options.”
The Sofinnova Telethon Fund is the largest fund entirely dedicated to biotechnology in Italy. The team is led by technology transfer specialists Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners, who are based in the firm’s Milan office.
The three new seed investments, totaling €6M, align with the fund’s investment strategy to seek out and support the best Italian science and the most promising entrepreneurs to develop world-class companies in the field of rare, genetic diseases.
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy. The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. Existing AAV-based platforms have been limited by capacity, and AAVantgarde Bio responds to this challenge by enabling delivery of large genes to tissue and cells in vivo. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Alia Therapeutics, based in Trento, is developing next generation CRISPR-based medicine for safer on-target in vivo gene editing approaches to the treatment of retinal degeneration. Alia is a spin-off of the University of Trento and was accelerated at BiovelocITA, Italy’s first biotechnology accelerator co-founded in 2015 by Sofinnova Partners and two serial entrepreneurs, Silvano Spinelli and Gabriella Camboni. It is the second company to emerge from the accelerator, following the success of Enthera Pharmaceuticals, another Italian startup that is part of Sofinnova Partners’ portfolio. This round of financing also included participation from BiovelocITA, Indaco Venture Partners, and a group of Italian investors brought together by Banor SIM and Banca Profilo.
Ms. Pozzi, Partner at Sofinnova Partners, board member of AAVantgarde Bio and an investment partner in Alia Therapeutics, commented: “We are delighted to support these innovative biotech startups as they advance promising programs towards preclinical and clinical development. Both companies have highly qualified scientific teams with globally recognized expertise in the field of gene therapy and gene editing. We are confident in the potential of these companies to tackle the limitations of existing therapies and develop treatments to diseases that do not have adequate solutions today.”
Borea Therapeutics, based in Milan, is advancing a new generation of gene therapies that would enable targeting of specific tissues and cells. The company’s innovative technology could enable viral vectors to reach areas like the central nervous system (CNS) and peripheral nervous system (PNS), thus opening the door to new therapeutic options. Borea Therapeutics was co-founded by Professor Paul Heppenstall and the European Molecular Biology Lab (EMBL), an intergovernmental research organization with six research sites throughout Europe, including one in Rome. The company’s research activities are performed in collaboration with Scuola Internazionale Superiore di Studi Avanzati (SISSA), a scientific center of excellence in Trieste.
Ms. Faccio, Partner at Sofinnova Partners and a board member of Borea Therapeutics, commented: “One of the major limitations of gene therapy is the difficulty of selectively targeting specific cells or tissues. Borea Therapeutics’ technology has the potential to pinpoint specific tissues and cells, which would enable the use of lower doses, making treatment safer and more effective for patients. This could be the next breakthrough in gene therapy.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs to Acquire U.S. Rare Earth and Critical Minerals Company Powering Defense and National Security14.5.2026 14:01:00 CEST | Press release
Proposed Acquisition Would Position Mobix Labs Inside Strategic U.S. Supply Chains Powering Defense, National Security, and AI Infrastructure Mobix Labs, Inc. (Nasdaq: MOBX) today announced it has signed a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a strategic infrastructure platform building sovereign U.S. supply chains for rare earth elements, critical minerals, and energy storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514342224/en/ U.S.A F-35 Lightning II The proposed acquisition would expand Mobix Labs — already a supplier to advanced U.S. and allied defense and aerospace systems — directly into one of the world's most strategically important industrial sectors. Key Facts at a Glance~418 kilogramsof rare earth materials are estimated to be used in each F-35 Lightning II. ~4,500 kilogramsof rare earth materials are estimated to be used in each Virginia-class nuclear submarine
Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy and Sovereignty Barriers14.5.2026 14:00:00 CEST | Press release
Demands for privacy and sovereignty expose limits of architectures built for centralized and borderless data flows. Data jurisdiction has become a core design parameter, shifting away from globally integrated systems to regionally bounded architectures. Organizations that redesign early are gaining a measurable edge in AI readiness and scale. NTT DATA, a global leader in AI, digital business and technology services, today released new research showing that enterprise AI is outgrowing the architecture and infrastructure beneath it as data privacy and sovereignty requirements tighten. The research finds a widening split between enterprises that are redesigning AI for control, locality and security, and organizations still layering AI into environments that were not built to support these requirements. For years, enterprise architecture moved data across systems, clouds, applications and borders with increasing speed and efficiency. AI is exposing the limits of that model. Sensitive data
Mary Kay Launches Global Social Squad Program to Empower the Next Generation of Digital Beauty Leaders14.5.2026 14:00:00 CEST | Press release
A Global Program Connecting 70+ Emerging Creators Among Independent Beauty Consultants with Digital Education, Mentorship, And Real‑World Beauty Brand Experience. Mary Kay Inc., a global leader in beauty and entrepreneurship, announces the launch of its Global Social Squad (GSS) Pilot Program – a groundbreaking initiative designed to empower Mary Kay Independent Beauty Consultants (IBCs) as dynamic digital brand advocates and next-generation social media storytellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514978222/en/ The Global Social Squad ignites a diverse and talented group of 73 Mary Kay Independent Beauty Consultants with representation across 15 markets in four regions: North America, Asia Pacific, Latin America, and Europe. These digital leaders create engaging, high-quality content, participate in global campaign activations, and share practical social media strategies with their communities and other I
Vista Equity Partners Establishes Abu Dhabi Office14.5.2026 14:00:00 CEST | Press release
Securing Full Regulatory Authorization from ADGM deepens Vista’s commitment to the Middle East and expands the firm’s global platform for enterprise software investing Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the opening of its new office in Abu Dhabi within ADGM, the city’s international financial center. VEPM Middle East Limited has received full authorization from ADGM’s Financial Services Regulatory Authority (FSRA), enabling the firm to advise on investments and arrange deals in investments across the region. The Abu Dhabi office reflects Vista’s expanded strategic presence in the Middle East and the region’s increasingly central role in global technology investment and innovation. Established in 2013, ADGM has emerged as one of the world’s leading financial centers, connecting global investors with regional opportunities. Vista joins a growing community of leading global investment firms that have estab
Eighteen48 Partners Announces First Close of Eighteen48 Private Equity Fund I at €175 million14.5.2026 13:56:00 CEST | Press release
Eighteen48 Partners today announced the first close of Eighteen48 Private Equity Fund I (the “Fund”) at €175 million. The Fund, which is targeting €350 million, is focused on European middle-market buyout transactions sourced through Independent Sponsors. Since 2020 Eighteen48 Partners have deployed more than €200 million into this strategy, which aims to provide investors with diversified exposure to off-market sourced transactions. The first close was supported by significant re-up commitments from Eighteen48 clients as well as commitments from institutions, family offices and UHNWs, underscoring the strength of the firm’s platform, track record and experience as well as growing momentum in the Independent Sponsor space. Julien Sevaux, Founding Partner and CEO, commented: “We are increasingly excited by the opportunity in the growing independent sponsor segment of European private equity - a corner of the market we believe remains largely overlooked by investors yet offers compelling
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom